We are an Oxford University spin-out developing breakthrough therapies for the treatment of ALS and other neurodegenerative diseases. Our approach builds upon novel protein isoform insights identified using our state-of-the-art technologies including long read sequencing and proprietary bioinformatics pipelines. Our founding team has decades of experience in the field of precision medicines, and we have an unwavering focus on developing novel therapies for patients. We are based in Oxford, UK (www.isogenixtx.com).

ISOgenix Limited

Org chart

Teams

Offices